Therapeutic Efficacy of Transcranial Magnetic Stimulation in Schizophrenia

Completed · Not applicable · Has a placebo group

Conditions studied: Schizophrenia

In brief

The aim of this study is to look at the effectiveness of repetitive transcranial magnetic stimulation (rTMS) as a therapeutic intervention for patients with schizophrenia. The primary outcome is improvement in negative symptoms related to schizophrenia. The investigators are focusing on negative symptoms given their greater resistance to pharmacological and other established therapies. If the investigators trial were to show beneficial effects, its clinical significance would be great.

Key facts

Study ID

NCT01551979

Run by

Beth Israel Deaconess Medical Center

People needed

22

Starts

2012-02-01

Expected to finish

2015-11-01

Last updated by the study team

2018-04-12

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age between 18-65 years
• Diagnosis of schizophrenia according to DSM-IV criteria (Diagnostic and Statistical Manual) by a board-certified psychiatrist

You may not qualify if…

• Preexisting or progressive neurological disorders
• Prior neurological procedures
• Previous head injury
• Change in antipsychotic medication during the last 4 weeks
• Been an inpatient in a psychiatry clinic within the last month
• Any other axis 1 diagnosis
• Patients may not be actively enrolled in a separate intervention study
• Patients unable to undergo a brain MRI
• Any unstable medical condition
• History of seizures, diagnosis of epilepsy, history of abnormal (epileptiform_ EEG, or family history of treatment resistant epilepsy
• Possible pregnancy. All female participants of child bearing age are required to have a pregnancy test.
• Any metal in the brain, skull, or elsewhere unless approved by the responsible MD
• Any medical devices (ie. cardiac pacemaker, deep brain stimulator, medication infusion pump, cochlear implant, vagal nerve stimulator) unless otherwise approved by the responsible MD
• Substance abuse (alcohol, amphetamines, cocaine, MDMA [methylenedioxymethamphetamine], ecstasy, PCP [phencyclidine], Angle dust) or dependence within the past six months
• No medication is an absolute exclusion from TMS. Medications will be reviewed by the responsible MD and a decision about inclusion will be made based on the following: the patient's past medical history, drug dose, history of recent medication changes or duration of treatment, and combination with other CNS (central nervous system) active drugs (the published TMS guidelines review of medications to be considered with TMS)

Where it is running

• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.